Arshad Khanani, MD, defines age-related macular degeneration as it relates to vision loss, highlighting the ways the condition may present in patients and its impact on quality of life.

Strategies that can be used to screen and confirm a diagnosis of age-related macular degeneration, as well as monitor patients to optimize care.

Dr Arshad Khanani describes the role of anti-VEGF therapy for wet age-related macular degeneration and elaborates on factors that impact treatment selection and sequencing in a patient’s continuum of care.

Based on personal clinical experience, Arshad Khanani, MD, explains his current approach to treating wet age-related macular degeneration with anti-VEGF therapy, with special considerations for appropriate dosage and timing of injections, and describes how he assesses patient response to therapy.

The rationale for studying faricimab, a bispecific antibody that targets 2 distinct pathways, as a treatment option for patients with wet age-related macular degeneration.

An overview of key clinical trials that have explored the potential of faricimab as a treatment option for patients with wet age-related macular degeneration.

Considerations for treating patients with diabetes who have wet age-related macular degeneration with faricimab to reduce treatment burden based on results of recent clinical trials.

Dr Arshad Khanani highlights various strategies currently under investigation for the treatment of age-related macular degeneration and explains the impact long-term data and real-world evidence has on his treatment decisions.